DK3442977T3 - Inhibitorer af activinreceptorlignende kinase - Google Patents
Inhibitorer af activinreceptorlignende kinase Download PDFInfo
- Publication number
- DK3442977T3 DK3442977T3 DK17733108.9T DK17733108T DK3442977T3 DK 3442977 T3 DK3442977 T3 DK 3442977T3 DK 17733108 T DK17733108 T DK 17733108T DK 3442977 T3 DK3442977 T3 DK 3442977T3
- Authority
- DK
- Denmark
- Prior art keywords
- kinase inhibitors
- activin receptor
- activin
- receptor
- kinase
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662322948P | 2016-04-15 | 2016-04-15 | |
| US201662411172P | 2016-10-21 | 2016-10-21 | |
| PCT/US2017/027775 WO2017181117A1 (en) | 2016-04-15 | 2017-04-14 | Inhibitors of activin receptor-like kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3442977T3 true DK3442977T3 (da) | 2023-10-09 |
Family
ID=59215888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17733108.9T DK3442977T3 (da) | 2016-04-15 | 2017-04-14 | Inhibitorer af activinreceptorlignende kinase |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10233186B2 (da) |
| EP (2) | EP3442977B1 (da) |
| JP (1) | JP7017521B2 (da) |
| KR (1) | KR102426043B1 (da) |
| CN (1) | CN109311889B (da) |
| AU (1) | AU2017250302B2 (da) |
| BR (1) | BR112018071184A2 (da) |
| CA (1) | CA3020870A1 (da) |
| CL (1) | CL2018002945A1 (da) |
| DK (1) | DK3442977T3 (da) |
| ES (1) | ES2957233T3 (da) |
| FI (1) | FI3442977T3 (da) |
| HU (1) | HUE063042T2 (da) |
| IL (1) | IL262345B (da) |
| MX (1) | MX2018012664A (da) |
| PH (1) | PH12018502205A1 (da) |
| PL (1) | PL3442977T3 (da) |
| PT (1) | PT3442977T (da) |
| SG (1) | SG11201808907PA (da) |
| WO (1) | WO2017181117A1 (da) |
| ZA (2) | ZA201807256B (da) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014011900A2 (en) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibitors of the fibroblast growth factor receptor |
| CA2905993C (en) | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| HUE059041T2 (hu) | 2013-10-17 | 2022-10-28 | Blueprint Medicines Corp | Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására |
| HUE059037T2 (hu) | 2013-10-25 | 2022-10-28 | Blueprint Medicines Corp | Fibroblaszt növekedési faktor receptor gátlók |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| PT3371171T (pt) | 2015-11-02 | 2024-01-24 | Blueprint Medicines Corp | Inibidores de ret |
| RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| UA124764C2 (uk) | 2016-04-15 | 2021-11-17 | Еббві Інк. | Інгібітори бромодомену |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| WO2018183712A1 (en) | 2017-03-31 | 2018-10-04 | Blueprint Medicines Corporation | Pyrrolo[1,2-b]pyridazine compounds and compositions useful for treating disorders related to kit and pdgfr |
| CA3060416A1 (en) | 2017-04-21 | 2018-10-25 | Epizyme, Inc. | Combination therapies with ehmt2 inhibitors |
| CN109081828B (zh) * | 2017-06-14 | 2021-03-26 | 上海时莱生物技术有限公司 | 聚(adp-核糖)聚合酶抑制剂、制备方法及用途 |
| CN111566102B (zh) | 2017-10-18 | 2023-09-08 | 缆图药品公司 | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 |
| CR20200522A (es) | 2018-04-03 | 2021-02-17 | Blueprint Medicines Corp | Inhibidor de ret para uso en tratar cáncer que tiene una alteración de ret |
| CN112512597A (zh) | 2018-07-26 | 2021-03-16 | 大日本住友制药肿瘤公司 | 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂 |
| CN109456253B (zh) * | 2019-01-11 | 2020-04-07 | 上海博璞诺科技发展有限公司 | 一种手性诱导合成(s)-3-(4-溴苯基)-哌啶或其盐的方法 |
| US20220281879A1 (en) * | 2019-08-13 | 2022-09-08 | Blueprint Medicines Corporation | Salt and crystal forms of an activin receptor-like kinase inhibitor |
| CN114502558A (zh) * | 2019-10-02 | 2022-05-13 | 缆图药品公司 | 制备活化素受体样激酶抑制剂的方法 |
| CN110698388A (zh) * | 2019-11-01 | 2020-01-17 | 暨明医药科技（苏州）有限公司 | 一种工业化生产(s)-3-(4-溴苯基)哌啶的方法 |
| AU2021409381A1 (en) * | 2020-12-21 | 2023-08-03 | Biocryst Pharmaceuticals, Inc. | Dosing regimens for oral alk2 kinase inhibitors |
| JP2024502601A (ja) * | 2021-01-07 | 2024-01-22 | バイオジェン・エムエイ・インコーポレイテッド | Ｔｙｋ２阻害剤 |
| WO2023247670A1 (en) * | 2022-06-24 | 2023-12-28 | F. Hoffmann-La Roche Ag | New heterocyclic-carbonyl-cyclic compounds as magl inhibitors |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1718309A2 (en) | 2004-01-30 | 2006-11-08 | Japan Tobacco, Inc. | Anorectic compounds |
| US20090176778A1 (en) | 2007-08-10 | 2009-07-09 | Franz Ulrich Schmitz | Certain nitrogen containing bicyclic chemical entities for treating viral infections |
| AR070127A1 (es) | 2008-01-11 | 2010-03-17 | Novartis Ag | Pirrolo - pirimidinas y pirrolo -piridinas |
| KR20120034613A (ko) * | 2009-04-16 | 2012-04-12 | 센트로 내셔널 드 인베스티가시오네스 온콜로지카스 (씨엔아이오) | 키나아제 억제제로서 사용을 위한 이미다조피라진 |
| AR077428A1 (es) | 2009-07-29 | 2011-08-24 | Sanofi Aventis | (aza) indolizinacarboxamidas ciclicas su preparacion y su uso como agentes farmaceuticos |
| WO2013134219A1 (en) * | 2012-03-09 | 2013-09-12 | Lexicon Pharmaceuticals, Inc. | Imidazo [1, 2 - b] pyridazine - based compounds, compositions comprising them, and uses thereof |
| PL2838900T3 (pl) | 2012-04-17 | 2020-02-28 | Gilead Sciences, Inc. | Związki i sposoby do leczenia przeciwwirusowego |
| CA2869954C (en) | 2012-04-20 | 2023-01-03 | Advinus Therapeutics Limited | Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof in medical conditions related to modulation of bruton's tyrosine kinase activity |
| WO2014011900A2 (en) | 2012-07-11 | 2014-01-16 | Blueprint Medicines | Inhibitors of the fibroblast growth factor receptor |
| TWI629266B (zh) | 2012-12-28 | 2018-07-11 | 藍印藥品公司 | 纖維母細胞生長因子受體之抑制劑 |
| WO2014138088A1 (en) * | 2013-03-04 | 2014-09-12 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| CA2905993C (en) * | 2013-03-14 | 2022-12-06 | Tolero Pharmaceuticals, Inc. | Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors |
| TW201444836A (zh) | 2013-03-14 | 2014-12-01 | Abbvie Inc | 吡咯并［２，３－ｂ］吡啶ｃｄｋ９激酶抑制劑 |
| EP2970289A1 (en) | 2013-03-15 | 2016-01-20 | Vertex Pharmaceuticals Inc. | Compounds useful as inhibitors of atr kinase |
| EP2970231A1 (en) | 2013-03-15 | 2016-01-20 | Blueprint Medicines Corporation | Piperazine derivatives and their use as kit modulators |
| WO2015058129A1 (en) | 2013-10-17 | 2015-04-23 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| HUE059041T2 (hu) | 2013-10-17 | 2022-10-28 | Blueprint Medicines Corp | Eljárás KIT-tel összefüggõ rendellenességek kezelésére alkalmas kompozíciók elõállítására |
| HUE059037T2 (hu) | 2013-10-25 | 2022-10-28 | Blueprint Medicines Corp | Fibroblaszt növekedési faktor receptor gátlók |
| US9695165B2 (en) | 2014-01-15 | 2017-07-04 | Blueprint Medicines Corporation | Inhibitors of the fibroblast growth factor receptor |
| TW201613916A (en) | 2014-06-03 | 2016-04-16 | Gilead Sciences Inc | TANK-binding kinase inhibitor compounds |
| US9688680B2 (en) | 2014-08-04 | 2017-06-27 | Blueprint Medicines Corporation | Compositions useful for treating disorders related to kit |
| CN106999509A (zh) | 2014-08-05 | 2017-08-01 | 艾丽奥斯生物制药有限公司 | 用于治疗副粘病毒的联合治疗 |
| WO2016127074A1 (en) | 2015-02-06 | 2016-08-11 | Blueprint Medicines Corporation | 2-(pyridin-3-yl)-pyrimidine derivatives as ret inhibitors |
| JP6827954B2 (ja) | 2015-04-16 | 2021-02-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | ３−（１ｈ−ベンズイミダゾール−２−イル）−１ｈ−ピリジン−２−オン誘導体 |
| BR112018001190A2 (pt) | 2015-07-24 | 2018-09-11 | Blueprint Medicines Corp | composições úteis para tratar distúrbios relacionados a kit e pdfgr |
| WO2017035354A1 (en) | 2015-08-26 | 2017-03-02 | Blueprint Medicines Corporation | Compounds and compositions useful for treating disorders related to ntrk |
| PT3371171T (pt) | 2015-11-02 | 2024-01-24 | Blueprint Medicines Corp | Inibidores de ret |
| RU2018122089A (ru) | 2015-11-19 | 2019-12-25 | Блюпринт Медсинс Корпорейшн | Соединения и композиции, подходящие для лечения расстройств, связанных с ntrk |
| US10183928B2 (en) | 2016-03-17 | 2019-01-22 | Blueprint Medicines Corporation | Inhibitors of RET |
| FI3442977T3 (fi) | 2016-04-15 | 2023-09-26 | Blueprint Medicines Corp | Aktiviinireseptorin kaltaisen kinaasin estäjät |
| WO2018017983A1 (en) | 2016-07-22 | 2018-01-25 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to ret |
| US10035789B2 (en) | 2016-07-27 | 2018-07-31 | Blueprint Medicines Corporation | Compounds useful for treating disorders related to RET |
| CN110022900A (zh) | 2016-09-08 | 2019-07-16 | 蓝图药品公司 | 成纤维细胞生长因子受体4抑制剂与细胞周期蛋白依赖性激酶抑制剂的组合 |
| US10280172B2 (en) * | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
-
2017
- 2017-04-14 FI FIEP17733108.9T patent/FI3442977T3/fi active
- 2017-04-14 SG SG11201808907PA patent/SG11201808907PA/en unknown
- 2017-04-14 HU HUE17733108A patent/HUE063042T2/hu unknown
- 2017-04-14 EP EP17733108.9A patent/EP3442977B1/en active Active
- 2017-04-14 ES ES17733108T patent/ES2957233T3/es active Active
- 2017-04-14 US US15/488,257 patent/US10233186B2/en active Active
- 2017-04-14 JP JP2018553961A patent/JP7017521B2/ja active Active
- 2017-04-14 BR BR112018071184-5A patent/BR112018071184A2/pt active Search and Examination
- 2017-04-14 CN CN201780035906.9A patent/CN109311889B/zh active Active
- 2017-04-14 PL PL17733108.9T patent/PL3442977T3/pl unknown
- 2017-04-14 KR KR1020187032927A patent/KR102426043B1/ko active IP Right Grant
- 2017-04-14 DK DK17733108.9T patent/DK3442977T3/da active
- 2017-04-14 AU AU2017250302A patent/AU2017250302B2/en active Active
- 2017-04-14 PT PT177331089T patent/PT3442977T/pt unknown
- 2017-04-14 EP EP23181727.1A patent/EP4285996A3/en active Pending
- 2017-04-14 CA CA3020870A patent/CA3020870A1/en active Pending
- 2017-04-14 WO PCT/US2017/027775 patent/WO2017181117A1/en active Application Filing
- 2017-04-14 MX MX2018012664A patent/MX2018012664A/es unknown
-
2018
- 2018-10-14 IL IL262345A patent/IL262345B/en unknown
- 2018-10-15 PH PH12018502205A patent/PH12018502205A1/en unknown
- 2018-10-16 CL CL2018002945A patent/CL2018002945A1/es unknown
- 2018-10-30 ZA ZA2018/07256A patent/ZA201807256B/en unknown
-
2019
- 2019-03-05 US US16/293,317 patent/US10669277B2/en active Active
-
2020
- 2020-05-29 US US16/887,262 patent/US11634422B2/en active Active
- 2020-08-27 ZA ZA2020/05341A patent/ZA202005341B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3442977T3 (da) | Inhibitorer af activinreceptorlignende kinase | |
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3303334T3 (da) | Tyrosinkinasehæmmere | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3419625T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| DK3497086T3 (da) | Aminopyrimidin-SSAO-inhibitorer | |
| DK3419624T3 (da) | Fremgangsmåder til anvendelse af fxr-agonister | |
| CL2016002502A1 (es) | Inhibidores de biaril cinasa | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| MA42242A (fr) | Inhibiteurs de la tyrosine kinase | |
| PL3305788T3 (pl) | Inhibitor kinazy janusowej | |
| DK3300500T3 (da) | Triazolagonister af apj-receptoren | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3307271T3 (da) | Fremgangsmåder til anvendelse af pyruvatkinase-aktivatorer | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3290418T3 (da) | Janus Kinase (JAK)-hæmmere | |
| DK3126373T3 (da) | Fremgangsmåde til fremstilling af amg 416 | |
| DK3555074T3 (da) | Aminopyrazoler som selektive januskinasehæmmere | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3681884T3 (da) | Rad51-inhibitorer | |
| DK3341379T3 (da) | EZH2-hæmmere | |
| MA43367A (fr) | Inhibiteurs de métallo-bêta-lactamases | |
| DK3114235T3 (da) | Fremgangsmåde til bestemmelse af risiko for 5-fluorouracil-toksicitet |